Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

van der Heijde, Désirée M; Revicki, Dennis A; Gooch, Katherine L; Wong, Robert L; Kupper, Hartmut; Harnam, Neesha; Thompson, Chris; Sieper, Joachim

doi:10.1186/ar2790

Table 4 Change in mean PRO measures from baseline to week 24 and follow-up visits^a

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

	Time point from baseline of the ATLAS study
PRO measure	Week 24	Week 36	Week 52	Week 76	Week 104	Week 128	Week 156
BASDAI
n	288	278	274	270	262	242	236
Mean ± SD change	-3.1 ± 2.42	-3.4 ± 2.41	-3.5 ± 2.55	-3.8 ± 2.33	-3.9 ± 2.44	-3.9 ± 2.39	-3.9 ± 3.39
BASFI
n	288	^b	274	270	261	242	236
Mean ± SD change	-2.2 ± 1.91	^b	-2.6 ± 2.04	-2.8 ± 2.10	-2.9 ± 2.14	-2.9 ± 2.17	-3.0 ± 2.10
SF-36 PCS
n	284	^b	265	263	255	229	227
Mean ± SD change	8.2 ± 9.01	^b	10.19 ± 9.50	10.8 ± 9.88	11.0 ± 9.88	11.3 ± 9.68	11.6 ± 9.65
SF-36 MCS
n	284	^b	265	263	255	229	227
Mean ± SD change	4.8 ± 10.27	^b	5.6 ± 10.35	5.1 ± 11.06	5.7 ± 10.96	4.1 ± 10.84	5.6 ± 11.59
SF-36 Physical Function
n	287	^b	273	268	261	241	235
Mean ± SD change	15.6 ± 20.99	^b	19.5 ± 21.38	21.8 ± 21.79	21.9 ± 22.26	22.2 ± 22.34	23.3 ± 21.94
SF-36 Role–Physical
n	288	^b	272	270	263	237	232
Mean ± SD change	30.3 ± 40.48	^b	37.2 ± 40.81	35.2 ± 40.72	39.1 ± 41.75	36.1 ± 42.39	37.8 ± 43.90
SF-36 Bodily Pain
n	288	^b	274	270	263	237	233
Mean ± SD change	24.0 ± 21.78	^b	29.0 ± 22.96	29.7 ± 23.24	29.9 ± 23.74	31.8 ± 24.42	31.7 ± 24.33
SF-36 General Health
n	287	^b	270	266	260	237	234
Mean ± SD change	8.7 ± 17.37	^b	11.3 ± 18.68	12.7 ± 19.25	12.5 ± 19.92	12.0 ± 18.84	12.7 ± 18.71
SF-36 Vitality
n	288	^b	274	268	263	242	236
Mean ± SD change	16.3 ± 19.82	^b	19.5 ± 19.96	20.1 ± 19.65	20.4 ± 20.05	18.4 ± 19.85	20.1 ± 19.70
SF-36 Social Function
n	288	^b	274	270	263	242	236
Mean ± SD change	16.1 ± 23.88	^b	19.7 ± 24.50	18.5 ± 23.73	20.6 ± 25.36	17.9 ± 26.01	22.3 ± 25.16
SF-36 Role–Emotional
n	286	^b	271	268	260	235	230
Mean ± SD change	17.2 ± 41.24	^b	21.0 ± 44.40	19.5 ± 46.74	21.5 ± 46.01	16.9 ± 44.80	20.0 ± 46.06
SF-36 Mental Health
n	288	^b	274	268	263	242	236
Mean ± SD change	8.8 ± 16.52	^b	10.1 ± 17.15	10.2 ± 17.50	10.6 ± 16.63	8.7 ± 16.96	10.5 ± 18.32
ASQOL
n	288	^b	274	270	263	242	236
Mean ± SD change	-4.1 ± 4.23	^b	-4.8 ± 4.41	-5.0 ± 4.32	-5.4 ± 4.28	-5.3 ± 4.35	-5.4 ± 4.36

^aAll values P < 0.001 compared with baseline based on paired Student t-test.
^bMeasure not assessed at this time point.
ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; MCS = Mental Component Summary; PCS = Physical Component Summary; PRO = patient-reported outcome; SD = standard deviation; SF-36 = Short Form-36 Health Survey.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us